Insider Buying: PureTech Health (LON:PRTC) Insider Buys 50,000 Shares

PureTech Health plc (LON:PRTC) insider John LaMattina bought 50,000 shares of PureTech Health stock in a transaction dated Wednesday, July 8th. The stock was acquired at an average cost of GBX 119 per share, with a total value of £59,500.

PureTech Health Stock Performance

Shares of PRTC opened at GBX 120 on Thursday. The stock has a 50 day moving average of GBX 129.88 and a 200 day moving average of GBX 127.13. The company has a market capitalization of £292.10 million, a price-to-earnings ratio of -2.61 and a beta of 0.79. PureTech Health plc has a 12 month low of GBX 104.71 and a 12 month high of GBX 148. The company has a current ratio of 6.59, a quick ratio of 2.51 and a debt-to-equity ratio of 6.33.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.